Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C38H64O49S7 |
| Molecular Weight | 1529.34 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 25 / 25 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]5(O[C@H]1[C@H](OC)[C@@H](OC)[C@]([H])(O[C@@H]2[C@@H](COS(O)(=O)=O)O[C@]([H])(O[C@H]3[C@H](OC)[C@@H](OC)[C@]([H])(O[C@@H]4[C@@H](COS(O)(=O)=O)O[C@H](OC)[C@H](OS(O)(=O)=O)[C@H]4OS(O)(=O)=O)O[C@H]3C(O)=O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)O[C@@H]1C(O)=O)O[C@H](COS(O)(=O)=O)[C@@H](OC)[C@H](OC)[C@H]5OC
InChI
InChIKey=AJBMORBNKXNZSF-COSHMZDQSA-N
InChI=1S/C38H64O49S7/c1-64-15-12(9-72-88(43,44)45)76-35(27(68-5)18(15)65-2)80-21-19(66-3)28(69-6)37(82-25(21)32(39)40)79-17-14(11-74-90(49,50)51)77-38(31(87-94(61,62)63)24(17)85-92(55,56)57)81-22-20(67-4)29(70-7)36(83-26(22)33(41)42)78-16-13(10-73-89(46,47)48)75-34(71-8)30(86-93(58,59)60)23(16)84-91(52,53)54/h12-31,34-38H,9-11H2,1-8H3,(H,39,40)(H,41,42)(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54)(H,55,56,57)(H,58,59,60)(H,61,62,63)/t12-,13-,14-,15-,16-,17-,18+,19+,20+,21+,22+,23+,24+,25+,26-,27-,28-,29-,30-,31-,34+,35-,36-,37-,38-/m1/s1
Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. However, clinical trials have revealed that idraparinux had lead to bleeding. As a result, Sanofi stopped the development of the drug.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. | 2008 Jan 26 |
|
| Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disorders. | 2008 May |
|
| Idraparinux and idrabiotaparinux. | 2010 Jan |
Sample Use Guides
The administration of idraparinux in subcutaneous fixed doses of 2.5 mg once weekly was found to be as effective and safe as conventional antithrombotic therapy in the initial treatment of patients with deep vein thrombosis, but less effective than standard therapy in the initial treatment of patients with primary pulmonary embolism
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
IDRAPARINUX
Created by
admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
|
PRIMARY | |||
|
100000092150
Created by
admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
|
PRIMARY | |||
|
6ADD3H8MFZ
Created by
admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
|
PRIMARY | |||
|
162610-17-5
Created by
admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
|
PRIMARY | |||
|
C479958
Created by
admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
|
PRIMARY | |||
|
DTXSID801027578
Created by
admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
|
PRIMARY | |||
|
DB06406
Created by
admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
|
PRIMARY | |||
|
3083445
Created by
admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
|
PRIMARY | |||
|
SUB25476
Created by
admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
|
PRIMARY | |||
|
m6202
Created by
admin on Fri Dec 15 21:31:57 GMT 2023 , Edited by admin on Fri Dec 15 21:31:57 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
